Analysts Set Valeant Pharmaceuticals Intl Inc (VRX) PT at $22.50
Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) have earned a consensus recommendation of “Hold” from the five ratings firms that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is C$22.50.
VRX has been the topic of several research analyst reports. Royal Bank Of Canada decreased their price target on shares of Valeant Pharmaceuticals Intl to C$22.50 and set a “sector perform” rating on the stock in a report on Friday, October 20th. TD Securities increased their target price on Valeant Pharmaceuticals Intl to C$26.00 and gave the company a “hold” rating in a research note on Wednesday, July 12th.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/analysts-set-valeant-pharmaceuticals-intl-inc-vrx-pt-at-22-50/1674013.html.
In other news, Director Schutter Richard Urbain De bought 4,900 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average price of C$14.35 per share, with a total value of C$70,315.00. Also, Director John Paulson sold 24,700 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of C$14.66, for a total value of C$362,102.00.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.